ACSM6
Acyl-coenzyme A synthetase ACSM6, mitochondrial
Also known as: ACSM6_HUMAN, bA310E22.3, C10orf129
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6P461
- Gene
- ACSM6
- Ensembl
- ENSG00000173124
- Chromosome
- 10
- Canonical length
- 480 aa
- Protein class
- Enzymes, Predicted membrane proteins
OverviewNCBI Gene
Predicted to enable fatty acid ligase activity and fatty-acyl-CoA synthase activity. Predicted to be involved in acyl-CoA metabolic process and fatty acid biosynthetic process. Located in mitochondrion. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
480 residues, UniProt reviewed canonical sequence.
>Q6P461|ACSM6
1 MLGRFQPFSL VRSFRLGFEA CCYPNQKCAT QTIRPPDSRC LVQAVSQNFN FAKDVLDQWS
61 QLEKDGLRGP YPALWKVSAK GEEDKWSFER MTQLSKKAAS ILSDTCALSH GDRLMIILPP
121 TPEAYWICLA CVRLGITFVP GSPQLTAKKI RYQLRMSKAQ CIVANEAMAP VVNSAVSDCP
181 TLKTKLLVSD KSYDGWLDFK KLIQVAPPKQ TYMRTKSQDP MAIFFTKGTT GAPKMVEYSQ
241 YGLGMGFSQA SRRWMDLQPT DVLWSLGDAF GGSLSLSAVL GTWFQGACVF LCHMPTFCPE
301 TVLNVLSRFP ITTLSANPEM YQELLQHKCF TSYRFKSLKQ CVAAGGPISP GVIEDWKRIT
361 KLDIYEGYGQ TETGLLCATS KTIKLKPSSL GKPLPPYIVQ IVDENSNLLP PGEEGNIAIR
421 IKLNQPASLY CPHMVSWEEY ASARGHMLYL TGDRGIMDED GYFWWSGRVD DVANALGQRLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ACSM6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 2.9 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 2.9 nTPM
- thymus: 2.9 nTPM
- skin: 1.5 nTPM
- stomach: 1.5 nTPM
- urinary bladder: 0.8 nTPM
- parathyroid gland: 0.3 nTPM
Single-cell type
- epicardial cells: 189 nCPM
- urothelial cells: 98 nCPM
- rod photoreceptor cells: 77 nCPM
- adipocytes: 43 nCPM
- retinal bipolar cells: 37 nCPM
- cardiomyocytes: 28 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- white matter: 1.1 nTPM
- amygdala: 0.7 nTPM
- basal ganglia: 0.7 nTPM
- cerebral cortex: 0.7 nTPM
- hypothalamus: 0.6 nTPM
- midbrain: 0.6 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.01
- gnomAD pLI
- 0
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- ATP binding
- fatty acid ligase activity
- fatty-acyl-CoA synthase activity
- GTP binding
- medium-chain fatty acid-CoA ligase activity
- metal ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ACSM6 as an antibody target. Whether an autoantibody or antibody against ACSM6 could matter depends on whether native ACSM6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ACSM6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ACSM6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...